Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis

This retrospective real-world evidence study investigates the efficacy of as-needed dosing of tildrakizumab in patients with mild-to-moderate psoriasis. Patients received the first three standard doses of tildrakizumab, and thereafter used as-needed dosing over the course of 2.5 years, rather than t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental dermatology 2024-02, Vol.49 (3), p.272-273
Main Authors: Abbad-Jaime de Aragón, Carlota, Berna-Rico, Emilio, Goas, Almudena, Pérez-Bootello, Javier, Ballester-Martinez, María Asunción, Jaén, Pedro, Blauvelt, Andrew, González-Cantero, Álvaro
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - therapeutic use
Humans
Induction Chemotherapy
Psoriasis - drug therapy
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This retrospective real-world evidence study investigates the efficacy of as-needed dosing of tildrakizumab in patients with mild-to-moderate psoriasis. Patients received the first three standard doses of tildrakizumab, and thereafter used as-needed dosing over the course of 2.5 years, rather than the approved interval of every 12 weeks. Adequate disease control was achieved, reaching a mean Psoriasis Area and Severity Index at the end of follow-up of < 1.
ISSN:0307-6938
1365-2230
DOI:10.1093/ced/llad361